303 related articles for article (PubMed ID: 19449004)
21. Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists.
Ghosh TK; Mickelson DJ; Lipson KE; Alkan SS
Int Immunopharmacol; 2007 Nov; 7(11):1471-82. PubMed ID: 17761351
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of NK cell function against head and neck cancer in response to ss-isRNA requires TLR7.
Pries R; Wulff S; Kesselring R; Börngen K; Xie L; Wollenberg B
Int J Oncol; 2008 Nov; 33(5):993-1000. PubMed ID: 18949362
[TBL] [Abstract][Full Text] [Related]
23. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities.
Philbin VJ; Levy O
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1485-91. PubMed ID: 18031250
[TBL] [Abstract][Full Text] [Related]
24. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis.
Hattermann K; Picard S; Borgeat M; Leclerc P; Pouliot M; Borgeat P
FASEB J; 2007 May; 21(7):1575-85. PubMed ID: 17264163
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in Acute Myeloid Leukemia.
Nourizadeh M; Masoumi F; Memarian A; Alimoghaddam K; Moazzeni SM; Hadjati J
Leuk Res; 2012 Sep; 36(9):1193-9. PubMed ID: 22579107
[TBL] [Abstract][Full Text] [Related]
26. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission.
Torelli GF; Guarini A; Palmieri G; Breccia M; Vitale A; Santoni A; Foa R
Br J Haematol; 2002 Feb; 116(2):299-307. PubMed ID: 11841430
[TBL] [Abstract][Full Text] [Related]
27. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.
Spaner DE; Shi Y; White D; Mena J; Hammond C; Tomic J; He L; Tomai MA; Miller RL; Booth J; Radvanyi L
Leukemia; 2006 Feb; 20(2):286-95. PubMed ID: 16341037
[TBL] [Abstract][Full Text] [Related]
30. TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1.
Triantafilou K; Vakakis E; Orthopoulos G; Ahmed MA; Schumann C; Lepper PM; Triantafilou M
Eur J Immunol; 2005 Aug; 35(8):2416-23. PubMed ID: 16025564
[TBL] [Abstract][Full Text] [Related]
31. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
Gorden KB; Gorski KS; Gibson SJ; Kedl RM; Kieper WC; Qiu X; Tomai MA; Alkan SS; Vasilakos JP
J Immunol; 2005 Feb; 174(3):1259-68. PubMed ID: 15661881
[TBL] [Abstract][Full Text] [Related]
32. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
[TBL] [Abstract][Full Text] [Related]
33. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
Johnson TR; Rao S; Seder RA; Chen M; Graham BS
Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
[TBL] [Abstract][Full Text] [Related]
34. Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia.
Zhong G; Jin G; Zeng W; Yu C; Li Y; Zhou J; Zhang L; Yu L
Int J Med Sci; 2020; 17(15):2346-2356. PubMed ID: 32922200
[No Abstract] [Full Text] [Related]
35. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
Toka FN; Nfon CK; Dawson H; Golde WT
Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
[TBL] [Abstract][Full Text] [Related]
36. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.
Jurk M; Heil F; Vollmer J; Schetter C; Krieg AM; Wagner H; Lipford G; Bauer S
Nat Immunol; 2002 Jun; 3(6):499. PubMed ID: 12032557
[No Abstract] [Full Text] [Related]
37. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.
Dudek AZ; Yunis C; Harrison LI; Kumar S; Hawkinson R; Cooley S; Vasilakos JP; Gorski KS; Miller JS
Clin Cancer Res; 2007 Dec; 13(23):7119-25. PubMed ID: 18056192
[TBL] [Abstract][Full Text] [Related]
38. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
[TBL] [Abstract][Full Text] [Related]
39. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
van den Ancker W; van Luijn MM; Ruben JM; Westers TM; Bontkes HJ; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
Cancer Immunol Immunother; 2011 Jan; 60(1):37-47. PubMed ID: 20859626
[TBL] [Abstract][Full Text] [Related]
40. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation.
Hackstein H; Knoche A; Nockher A; Poeling J; Kubin T; Jurk M; Vollmer J; Bein G
Cell Immunol; 2011; 271(2):401-12. PubMed ID: 21889130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
